LYNX CAPITAL GROUP LTD /ADV’s Pfizer PFE Stock Holding History

LYNX CAPITAL GROUP LTD /ADV’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.36M	Buy	+47,336	New	+$1.43M	0.99%	45

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

LYNX CAPITAL GROUP LTD /ADV's PFE Position: Q4 2023 in Review

LYNX CAPITAL GROUP LTD /ADV opened a new position in Pfizer (PFE) in Q4 2023: 47,336 shares worth $1.36M. The stake represents 0.99% of the portfolio and ranks #45 among its holdings.

2,937 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

LYNX CAPITAL GROUP LTD /ADV held 47,336 shares of Pfizer worth $1.36M as of Q4 2023.
Pfizer was a new LYNX CAPITAL GROUP LTD /ADV position in Q4 2023.
Pfizer made up 0.99% of LYNX CAPITAL GROUP LTD /ADV's portfolio in Q4 2023, its #45 holding.
2,937 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on LYNX CAPITAL GROUP LTD /ADV's 13F filing for Q4 2023, filed 7 Aug 2026.